Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

  title={Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.},
  author={S. Grundy and J. Cleeman and C. N. Merz and H. Brewer and L. Clark and D. Hunninghake and R. Pasternak and Sidney C. Smith and N. Stone},
  journal={Arteriosclerosis, thrombosis, and vascular biology},
  volume={24 8},
The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for… Expand
Anticipating the evolution of clinical cholesterol guidelines: implications of recent statin intervention trials.
Review of recent trials indicates that improved methods of risk stratification and intensification of LDL-C goals are trends which are likely to continue into the future. Expand
Implications of emerging risk factors for therapeutic intervention.
The International Task Force for Prevention of Coronary Heart Disease responds to the National Cholesterol Education Panel commentary and supports the suggestion of more intensive LDL cholesterol lowering in particular cases. Expand
Application of new cholesterol guidelines to a population-based sample.
The new ACC-AHA guidelines for the management of cholesterol would increase the number of adults who would be eligible for statin therapy by 12.8 million, with the increase seen mostly among older adults without cardiovascular disease. Expand
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.
An expert panel convened by the National Lipid Association to evaluate the use of selected biomarkers to improve risk assessment, or to adjust therapy is described, intended to provide practical advice to clinicians who wrestle with the challenges of identifying the patients who are most likely to benefit from therapy. Expand
Has the adult treatment panel III guideline been updated?
  • W. Marcason
  • Medicine
  • Journal of the Academy of Nutrition and Dietetics
  • 2014
It must be emphasized that lifestyle modification remains a critical component of health promotion and CVD risk reduction, both prior to and in concert with the use of cholesterol-lowering drug therapies. Expand
Cholesterol treatment and changes in guidelines in an academic medical practice.
The ACC/AHA guidelines expand the number of patients recommended to receive statins, particularly among patients who were previously thought to be at moderate risk, and would increase the intensity of treatment for many patients at high risk. Expand
Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.
Major changes include a lower low-density lipoprotein cholesterol (LDL-C) treatment target for high-risk patients, a slightly higher intervention point for the initiation of drug therapy in most low-risk individuals and recommendations regarding additional investigations of potential use in the further evaluation of coronary artery disease risk in subjects in the moderate-risk category. Expand
Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin-Treated Subjects From 3 Data Sources: A Retrospective Analysis
There was consistency in the proportion of high-risk patients treated with statin monotherapy who were at LDL-C goal, and a significant number of these statin-treated patients had additional dyslipidemias. Expand
Rationale for Aggressive Lipid Lowering in High-Risk Patients
  • Jerome D. Cohen
  • Medicine
  • The Journal of the American Osteopathic Association
  • 2011
Overall, the data convincingly demonstrate that LDL-C lowering is associated with a significant reduction in CHD events, regardless of preexisting CHD, and should be addressed in the NCEP ATP IV guidelines, scheduled to be released in 2011. Expand
Diet and Cholesterol Reduction
The dietary approach in Gardner and colleagues' study reflects current thinking on how to increase the effectiveness of therapeutic diets and is an important reminder that diet, in addition to drugs, can play a role in achieving cholesterol targets. Expand